Related Experiment Videos
Randomized controlled trials in urologic oncology: a demographic analysis.
The Canadian Journal of Urology
|November 1, 1994
Summary
Randomized controlled trials (RCTs) in urologic oncology are limited, with few featuring surgical arms. This review highlights the need for more surgical oncology research and urologist involvement in RCTs.
Area of Science:
- Urologic Oncology
- Clinical Trials Research
Background:
- Randomized controlled trials (RCTs) are the gold standard for evaluating medical interventions.
- The landscape of urologic oncology research in 1992 was assessed to understand the role of RCTs.
Purpose of the Study:
- To analyze the characteristics of published randomized controlled trials in urologic oncology from 1992.
- To evaluate the contribution of urologists and the inclusion of surgical arms in these trials.
Main Methods:
- A structured MEDLINE search identified RCTs in bladder, prostate, testis, and renal carcinoma published in 1992.
- Data extracted included treatment modality, disease site, author, country, cohort size, funding, and journal type.
Main Results:
- 36 urologic oncology RCTs were identified, predominantly focusing on medical therapies (94%).
- Only 5 RCTs (14%) included a surgical arm, and urologists authored 67% of the papers.
- Most trials were multicenter (56%) with large cohorts (>100 patients in 67%), but 50% lacked stated funding sources.
Conclusions:
- While RCTs are conducted in urologic oncology, their number is relatively low compared to studies with less rigorous designs.
- There is a significant underrepresentation of surgical interventions within urologic oncology RCTs, indicating a need for increased surgical research.